Seizures in Cerebral Vein and Dural Sinus ThrombosisFerro J.M.a · Correia M.b · Rosas M.J.c · Pinto A.N.d · Neves G.e
Departments of Neurology,aHospital de Santa Maria, Lisboa, bSanto António, Porto, cSão João, Porto, dFernando da Fonseca, Amadora, and eSão Pedro, Vila Real, Portugal
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
To describe early symptomatic and late seizures in a cohort of patients with acute cerebral vein and dural sinus thrombosis (CVDST) and to identify their determinants, we performed a prospective registry and follow-up study of CVDST patients admitted to 20 Portuguese hospitals, from June 1995 to June 1998. Of 91 registered patients, 31 (34%) had early symptomatic seizures; 29 (31.9%) as a presenting feature and 2 (2.1%) after admission. Early symptomatic seizures were more frequent in patients with motor and sensory deficits and in those with focal oedema/ischaemic infarcts or haemorrhages on admission CT/MR. On multivariate logistic regression analysis, sensory defects (OR = 7.8; 95% CI = 0.8–74.8) and a parenchymal lesion on admission CT/MR (OR = 3.7, 95% CI = 1.4–9.4) were found to be significant predictors of early symptomatic seizures. Seizures were directly related to acute death in 2 patients. Eight (9.5%) patients had late seizures, which were multiple in 4 (4.8%). Late seizures were more frequent in patients with early symptomatic seizures and with haemorrhage on admission CT/MR. Neither early symptomatic seizures nor late seizures were related to functional prognosis at the last follow-up (median = 1 year). There is a moderate risk of seizure recurrence early in the course and during the first year after CVDST. Seizures can be a cause of acute death, but might not have an independent influence on functional outcome. Pharmacological prevention of seizures after CVDST should probably be limited to patients with early symptomatic seizures and cerebral lesions on admission CT/MR.
© 2003 S. Karger AG, Basel
Bousser MG, Russell RR: Cerebral venous thrombosis; in Warlow CP, Van Gijn J (eds): Major Problems in Neurology. London, WB Saunders, 1997, vol 33, pp 25, 140.
Nagpal RD: Dural sinus and cerebral venous thrombosis. Neurosurg Rev 1983;6:135–160.
- Srinivasan K: Cerebral venous and arterial thrombosis in pregnancy and puerperium. A study of 135 patients. Angiology 1983;34:731–746.
Milandre L, Gueriot C, Girard N, Ali Cherif A, Khalil R: Les thromboses veineuses cérébrales de l’adulte. Aspects diagnostiques et thérapeutiques à propos de 20 observations. Ann Med Interne 1988;139:544–554.
Kaplan JM, Biller J, Adams HP: Outcome in nonseptic spontaneous superior sagittal sinus thrombosis in adults. A 14-year experience. Cerebrovasc Dis 1991;1:231–234.
Rondepierre P, Hamon M, Leys D, Lederc X, Mournier-Vehrer F, Godefroy O, Janssens E, Pruvo JP: Thromboses veineuses cérébrales: Étude de l’évolution. Rev Neurol 1995;151:100–104.
- Preter M, Tzourio CH, Ameri A, Bousser MG: Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke 1996;27:243–246.1
Ferro JM, Correia M, Pontes C, Baptista MV, Pita F, for the Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport): Cerebral vein and dural sinus thrombosis in Portugal: 1980–1998. Cerebrovasc Dis 2001;11:177–182.
- Rankin J: Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scott Med J 1957;2:200–215.
- The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569–1581.
- Commission on Epidemiology and Prognosis, International League against Epilepsy: Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34:592–596.
Ferro JM, Lopes MG, Rosa MJ, Ferro MA, Fontes J: Long-term prognosis of cerebral vein and dural sinus thrombosis. Results of the VENOPORT study. Cerebrovasc Dis 2002;13:272–278.
Barinagarrementeria F, Cantu C, Arredondo H: Aseptic cerebral venous thrombosis: Proposed prognostic scale. J Stroke Cerebrovasc Dis 1992;2:34–39.
Pohlmann-Eden B, Cochius JI, Hoch DB, Hennerici MG: Stroke and epilepsy: Critical review of the literature. 2. Risk factors, pathophysiology and overlap syndromes. Cerebrovasc Dis 1997;7:2–9.
Kraemer DLA, Pizzonia JH: Vascular lesions as a cause of epilepsy; in Kotagel P, Lüders HO (eds): The Epilepsies: Etiologies and Prevention. San Diego, Academic Press, 1999, pp 385–390.
Pohlmann-Eden B, Hoch DB, Cochius JI, Hennerici MG: Stroke and epilepsy: Critical review of the literature. 1. Epidemiology and risk factors. Cerebrovasc Dis 1996;6:332–338.
Abbott AL, Bladin CF, Donnan GA: Seizures and stroke; in Bogousslavsky J, Caplan L (eds): Stroke Syndrome, ed 2. Cambridge, Cambridge University Press, 2001, pp 182–191.
- DeVeber G, Andrew M, Adams C, Bjornson B, Booth F, Buckley DJ, Camfield CS, David M, Humphreys P, Langevin P, MacDonald A, Gillet J, for the Canadian Pediatric Ischemic Stroke Study Group: Cerebral sinovenous thrombosis in children. N Engl J Med 2001;345:417–423.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.